National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations

Overview of attention for article published in Journal of Clinical Oncology, October 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 37 X users
guideline: 1 clinical guideline source

bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 61 X posts from 37 X users, with an upper bound of 148,171 followers.

@CedricPetersRT @EurUrolOncol @RomDiamand @VickersBiostats @f2harrell @JulesBordet https://t.co/NcR2qaUkjV https://t.co/GoySxPGzx7 https://t.co/NAAeWX7erz

RT @Dr_RaviMadan: @DrSpratticus @APCCC_Lugano @US_FDA @DrMakaryFDA 📖Cc:@davidjeinstein @melissaabel20 @Dr_JeannyAC @JulieGr28180604 @RPachy…

@DrSpratticus @APCCC_Lugano @US_FDA @DrMakaryFDA 📖Cc:@davidjeinstein @melissaabel20 @Dr_JeannyAC @JulieGr28180604 @RPachynski @EdwinPosadasMD @krishnan_patel @DeborahCitrin @HelenMoonMD @FatimaKarzai @ArlenParlen @mbilusic @MarkowskiGUOnc @PChoyke @laura…

RT @davidjeinstein: @TylerSbrt @piet_ost @KOSJ12 @APCCC_Lugano Such a tricky but important disease space! Worth its own working group! htt…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 57 additional X posts.